Yesterday, a Director at La Jolla Pharma, Laura Douglass, exercised options of La Jolla Pharma (NASDAQ: LJPC) for $3,000.
Following this transaction Laura Douglass’ holding in the company was increased by 100% to a total of $16.04K.
See today’s analyst top recommended stocks >>
Based on La Jolla Pharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $809K and GAAP net loss of $50.53 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $23.24 million. Currently, La Jolla Pharma has an average volume of 357.3K.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $52.67, reflecting a -39.1% downside. 12 different firms, including B.Riley FBR and BTIG, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.
